7th Annual BioPartnering North America
February 8-10, 2009 | Vancouver, BC, Canada
|
 |
7th Annual BioPartnering North America
February 8-10, 2009 | Vancouver, BC, Canada  |
||
 |
 2008 Program+ EXPAND all sections 
To expand/collapse individual sections, click the section title or grey arrow. Sunday, February 35:30-6:00 Registration
6:00-8:00 Opening Reception
Title: Vancouver Welcomes the Global Biotech Community Sponsored by: Farris, Vaughan, Wills & Murphy Monday, February 48:00-8:30 Registration & Continental Breakfast
Sponsored by: VWR International 8:30-8:45 Conference Welcome
Speaker: Mr. Peter Brenders, President & CEO, BIOTECanada Speaker: Ms. Karimah Es Sabar, President, LifeSciences British Columbia Speaker: Mr. Don Fast, Deputy Minister, Ministry of Economic Development Speaker: Dr. Robert Lee Kilpatrick, Partner, Technology Vision Group LLC Speaker: Mr. Stephen Mandel, Mayor, City of Edmonton Speaker: Mr. Ryan Radke, President, BioAlberta 8:45-10:00 BioPartnering Leadership Session 1
Title: Deal-Making in Biopharmaceuticals: A State of the Industry Review The panel topics will include:
Chair: Mr. James D. Watson, Managing Director and Head of Merchant Banking, Burrill & Company Speaker: Dr. Tony Coles MD, President & CEO, NPS Pharmaceuticals Speaker: Mrs. Kathleen Sereda Glaub, President, Plexxikon Inc. Speaker: Dr. Corinne Savill, Global BD&L, Head Search & Evaluation GM Novartis, Novartis 9:45-11:45 Open House Booth Presentations - Group 1
Fourteen international biopharmaceutical and diagnostic companies will host two-hour interactive multimedia sessions. Partnering teams, including scientists will be available for informal discussions. 10:00-11:00 Workshop - hosted by Wilson Sonsini Goodrich & Rosati
Title: Biotechnology Deal Making In this interactive, hand-on workshop, WSGR's life sciences experts, as well as life sciences industry leaders, will analyze and discuss terms that can be employed successfully in partnering agreements. Our experts will discuss negotiating strategies, key provisions and potential pitfalls and problem areas. Speaker: Mr. Kenneth A. Clark, Partner, Wilson, Sonsini, Goodrich & Rosati Speaker: Mr. Eric Dobmeier, Chief Business Officer, Seattle Genetics, Inc. Speaker: Ms. Effie Toshav, Attorney, Wilson Sonsini Goodrich & Rosati 10:00-12:15 Open House Podium Presentations
In this dedicated Open House presentation room, presenters have the opportunity to briefly introduce their company, highlight key technologies, alliances, and where they stand with product & clinical developments.
10:00-12:15 Emerging Company Presentations
Nine emerging biotechnology companies from around the world will offer 14-minute company presentations. Companies will be available for follow up meetings after the presentations. Moderator: Mr. Soren Harbel, VP,Innovation Development, BC Innovation Council
11:15-12:15 Workshop - hosted by Ferghana Partners Group
Title: Using Probability Weighted Product Models to Optimize Corporate Partnering Negotiations When negotiating large and/or complex corporate partnering deals, there are some key challenges, which are:
This workshop will focus on case studies of licensing deals and will go thru the steps and the rationale of putting together a probability weighted model and a Delphi grid that are intended to drive and guide the negotiations for the partnering deal. Speaker: Mr. William J Kridel, Founder, Managing Director, Ferghana Partners Group Speaker: Mr. Matthew Symonds, Senior Associate, Ferghana Partners Group 12:15-1:15 Lunch
Sponsored by: BC Innovation Council 1:15-1:30 BIOTECanada/TVG Student Scholarship Awards Ceremony
Technology Vision Group LLC (TVG) is strongly committed to the Canadian biotechnology industry. Together with BIOTECanada, we finance full scholarships to allow students from across Canada to attend BPN. We invest in Canadian biotech now because we believe in the future of a vibrant biotech industry of Canada. The recipients of the scholarships will be introduced. Speaker: Mr. Peter Brenders, President & CEO, BIOTECanada 1:15-4:30 Emerging Company Presentations
Thirteen emerging biotechnology companies from around the world will offer 14-minute company presentations. Companies will be available for follow up meetings after the presentations. Moderator: Mr. Soren Harbel, VP, Innovation Development, BC Innovation Council
1:30-2:45 BioPartnering Leadership Session 2
Title: Making a Great Deal: Ingredients for Success Biopharma deal-making is a bit like cooking. Different ingredients are needed for a dish to be a success. This panel will focus on the ingredients of biopharma deals that make them a win/win for both sides and/or ingredients that may cause issues to arise. Biopharma deals are prone to fashions affected by the state of capital markets, the need by big pharma to access early-stage technologies and products, or near to market opportunities, and other factors. Each of the experts on this panel bring a wide variety of experiences related to biopharma deal-making to this discussion and are able to address both general and specific ingredients for success. Chair: Ms. Karimah Es Sabar, President, LifeSciences British Columbia Speaker: Mr. James P Hatton, Partner, Farris, Vaughan, Wills & Murphy LLP Speaker: Mr. Karl R Hermanns, Managing Partner, Seed IP Law Group PLLC Speaker: Mr. Gord R Jans, Partner, PricewaterhouseCoopers LLP 2:00-4:00 Open House Booth Presentations - Group 2
Fourteen international biopharmaceutical and diagnostic companies will host two-hour interactive multimedia sessions. Partnering teams, including scientists will be available for informal discussions. 2:15-3:45 Workshop - hosted by Italian Trade Commission
Title: Italian Life Sciences: Growth and Opportunities The Italian Biotechnology industry has been growing steadily over the past few years. With over 160 companies actively present in this sector, employing 8,400 people, and a turnover of 2.9 billion Euro, Italy ranks fourth in Europe after Germany, UK and France. Over 1 billion Euro of private R&D funds are invested annually in the Italian Life Sciences industry, making it one of the economy's most dynamic sectors in Italy and a location of choice for the most important multinational companies. This workshop will focus on the current Italian biotech scenario with growth perspectives and opportunities, showcasing testimonials from these successful Italian companies interested in the North American market. Speaker: Dr. Paolo Barbanti, CEO, Pharma & Biotech Advisors Speaker: Dr. Luigi Cavenaghi, President, ARETA INTERNATIONAL s.r.l. Speaker: Dr. Germano Ferrari, Business Development Manager, MolMed SpA Speaker: Dr. Massimo Grilli, Director, Business Development/Coordinator, EuroAlliance C/O Alfa Wassermann S.p.a Speaker: Dr. Francesco Lami, Director, Business Development, Italfarmaco Speaker: Dr. Maria Luisa Nolli, CEO, HO.p.e. Srl Speaker: Dr. Sinibaldo Perseu, President & CEO, bcs Biotech SpA Speaker: Dr. Andrew Slade, Managing Director, (MBH) A. Menarini I.F.R Speaker: Prof. Giorgio Stanta, Professor of Pathology, Universita' di Trieste 2:45-5:30 Open House Podium Presentations
In this dedicated Open House presentation room, presenters have the opportunity to briefly introduce their company, highlight key technologies, alliances, and where they stand with product & clinical developments.
4:15-5:30 BioPartnering Leadership Session 3
Title: Driving the Deal: Positioning for the Optimal Partnership or Being Acquired In the current environment, most business development executives and investors attempt a "multi-track" effort to produce an auction or competitive bidding scenario. This session will address the following questions:
Chair: Mr. Glen Y Sato, Partner, Cooley Godward Kronish LLP Speaker: Mr. Nicholas Adams, Director of Business Development, Antisoma Speaker: Mr. David N Low Jr., Managing Director, Lazard 4:30-5:30 Workshop - hosted by BioAlberta
Title: A New Partnering Frontier - Alberta, Canada Be part of living solutions and future success in a region with an abundance of energy in the ground and in creative minds Home to more than 100 life science companies, Alberta is North America's fastest growing economy and an emerging world class technology sector that has developed strong links with major, international partners and is seeking a larger place on the world stage. This workshop will profile research activity within Alberta's world-class health and biotechnology institutes and showcase companies that are active in the region. Join us in exploring this new bio-frontier.
Speaker: Dr. Gary Lopaschuk, Scientific Director, Mazankowski Heart Institute Speaker: Mr. Kimmo Lucas, President and CEO, Cardiometabolics Inc. Speaker: Dr. John Wallace, Founder and Chief Science Officer, Antibe Therapeutics 5:30-6:30 "Taste of Canada" Drinks Reception
Sponsored by: Marsh Canada Limited 6:30-8:30 Dinner and Casino Night
Tuesday, February 58:30-9:00 Continental Breakfast
9:00-10:15 BioPartnering Leadership Session 4
Title: M&A Deals – Upside and Downside or is it Upside Down and Downside Up? This panel will examine success and failure in the aftermath of an acquisition. All M&A deals start out their life with good intentions and high aspirations for the prosperity anticipated as a result of the transaction…but life is unpredictable…some deals succeed in adding value for shareholders and luster to their company reputation and others destroy value and tarnish everyone’s good name. There are obviously lessons to be learned as to why some deals SUCCEED and why some deals FAIL. Is it in the selection process for the deal itself or in the integration process after the deal is done or is it all attributable to personalities? Chair: Mr. William J. Kridel, Managing Director, Ferghana Partners Group Speaker: Ms. Pamela Demain, Executive Director, Corporate Licensing, Merck & Co., Inc. Speaker: Dr. Richard Douglas, Senior Vice President, Genzyme Corporation Speaker: Mr. Matthew Plunkett, Executive Director, Oppenheimer & Co. Speaker: Mr. Eric Victory, Senior Manager, Business Development, MedImmune, Inc. 9:30-10:30 Workshop - hosted by Morrison & Foerster
Title: Living With the Deal: Lasting Value in Partnering Agreements Deals, of course, aren't over when inked and announced. How well they've been done (and how well they protect value) for each side may not be apparent until the companies have operated under the deal documents for a while. In past years, we have explored the topic "Value Terms in Partnering Agreements: Going Beyond the Numbers" with a panel of industry veterans. This year, our panel will further develop this theme, with particular focus on living with the deal and the kind of enduring value that resides in clauses that stand the tests of time and strain as the relationship develops. This will include candid discussion of surprises, both positive and negative, that our panelists have encountered in living with their own deals (whether in the documents or in the partners, as they have evolved). We will share thoughts on the kinds of detailed provisions that may not make it into a term sheet, but are critical to making the deal livable and protecting value for the company in the long run under a variety of circumstances, expected and unexpected. Speaker: Ms. Susan Koppy, Business Development Executive, Speaker: Mr. Raul R. Rodriguez, EVP and COO, Rigel Pharmaceuticals Speaker: Ms. Laura O. Spiegelman, Partner, Morrison & Foerster Speaker: Mr. John J. Wulf, EVP & CBO, Trellis Bioscience, Inc. 9:30-11:30 Open House Booth Presentations - Group 3
Fourteen international biopharmaceutical and diagnostic companies will host two-hour interactive multimedia sessions. Partnering teams, including scientists will be available for informal discussions. 9:30-12:15 Open House Podium Presentations
In this dedicated Open House presentation room, presenters have the opportunity to briefly introduce their company, highlight key technologies, alliances, and where they stand with product & clinical developments.
10:45-11:45 Workshop - hosted by Cooley Godward Kronish LLP
Title: Dealmakers, Internal Support and Getting the Deal Done: The process, internal approvals and the mechanics of getting a deal that works for your company. Our workshop will discuss effective planning, licensing strategies and tactics and how to effectively shorten the deal cycle. We will focus on understanding the scope of the deal, when to use or avoid a term sheet, when to begin drafting documents and creating realistic expectations for completing a deal successfully. Speaker: Mr. Barclay J. Kamb, Partner, Cooley Godward Kronish LLP Speaker: Mr. Glen Y Sato, Partner, Cooley Godward Kronish LLP 11:00-11:20 Pharmaceutical Presentation - AstraZeneca
Title: Fostering Shared Growth 11:25-11:45 Pharmaceutical Presentation - Merck & Co., Inc.
Title: Partnering Update: Another Great Year for Merck and our Partners 2007 - another great year in which Merck and partners executed approximately 50 significant deals ranging from compounds in development to preclinical and technology collaborations. In this presentation, we will discuss Merck's partnering strategy, the new deals consummated in 2007 as well as provide an update on our partnerships in progress. Speaker: Ms. Pamela Demain, Executive Director, Corporate Licensing, Merck & Co., Inc. 11:50-12:10 Pharmaceutical Presentation - Novartis
12:15-1:15 Lunch
1:15-1:35 Pharmaceutical Presentation - Wyeth
1:30-2:30 Workshop - hosted by Province of British Columbia
Title: Partnership Development: British Columbia's Approaches to Commercializing Research Bridging the gap between academic research and product commercialization is always a challenge. Several representatives from British Columbia instititutions will talk about their experiences in moving the results of research projects to the market place. Speaker: Dr. Samuel Abraham, VP, Stategic Relationships, BC Cancer Agency Speaker: Ms. Natalie E. Dakers, CEO, Centre for Drug Research and Development Speaker: Dr. Alan Winter, President & CEO, Genome British Columbia 1:40-2:00 Pharmaceutical Presentation - Procter & Gamble Pharmaceuticals
Title: Looking at Healthcare Through a Different Lens 1:45-3:45 Open House Booth Presentations - Group 4
Fourteen international biopharmaceutical and diagnostic companies will host two-hour interactive multimedia sessions. Partnering teams, including scientists will be available for informal discussions. 2:05-2:25 Pharmaceutical Presentation - Roche
2:30-2:50 Pharmaceutical Presentation - Pfizer, Inc.
Title: Pfizer an Emerging Leader in Oncology 2:55-3:15 Pharmaceutical Presentation - Bristol-Myers Squibb Company
3:45-5:00 BioPartnering Leadership Session 5
Title: Financing Strategies for Biotech Companies Given the need for capital in drug development, many successful models have evolved in the industry. The options include equity (both in the public and private markets), strategic collaborations, debt and other creative deal structures. In this session, a panel of experts will analyze specific deal structures and highlight examples that were important in the industry in 2006-2007. Chair: Mr. Mark Handfelt, Partner, Wilson Sonsini Goodrich & Rosati Speaker: Mr. David R. Horn, Executive Director, Morgan Stanley Speaker: Ms. Buu Le Lien, Senior Manager, Corporate Business Development, Eli Lilly and Company Speaker: Dr. Robert Mashal, Chief Executive Officer, Alinea Pharmaceuticals, Inc. Speaker: Dr. Corinne Savill, Global BD&L, Head Search & Evaluation GM Novartis, Novartis 5:00-6:00 Closing Drinks
Sponsored by: UK Trade & Investment |
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Join us for dinner and a fun-filled night! Try out your luck with “BioPartnering Bucks” at the various gambling tables, including blackjack, Texas hold’em, craps, roulette and the money wheels! Then cash in at the end of the night to see if you’re the high winner!!